TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26611120
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Nutraceuticals + Ezetimibe)
Study: 19539099
Drug: ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 5 mg/d (low-dose group)
Study: 19539099
Drug: ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 10 mg/d (high-dose group)
Study: 19539099
Drug: ramipril (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (both formulations)
Study: 16432050
Drug: Chlorthalidone 12.5
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5 mg/day
Study: 11560454
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole followed by oral itraconazole solution
Study: 11915854
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/day
Study: 9158080
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg + MPA 2.5 mg/day
Study: 9158080
Drug: CEE 0.31
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.31 mg + MPA 2.5 mg/day
Study: 9158080
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg alone or with MPA
Study: 19169336
Drug: Selenium and
Normalized name: Selenium and/or selenium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium and aspirin (SAM)
Study: 10746892
Drug: Standardized soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized soy extract (SOYSELECT) 400 mg/day
Study: 10390097
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day
Study: 8777352
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI); 127 metaphase II oocytes injected.
Study: 29343012
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment regimen (2SHRZE/6HRE) with drug replacement based on DST results, treatment duration of 12 months or more if drug resistance is present, otherwise 8 months standard treatment.
Study: 29343012
Drug: Intensified retreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified retreatment regimen (2HL(2)EZS/2HL(2)EZS(3)/4HL(2)E) with specific dosing based on body weight, total treatment duration of 8 months.
Study: 29343012
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment regimen (2HREZS/6HRE) recommended by national tuberculosis program, total treatment duration of 8 months.
Study: 16616557
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C and 400 IU vitamin E daily from the second trimester until delivery
Study: 16616557
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo daily from the second trimester until delivery
Study: 11783744
Drug: l‐alpha‐acetylmethadol (LAAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐alpha‐acetylmethadol (LAAM)
Study: 8293297
Drug: Oral inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral inositol treatment
Study: 3318427
Drug: Nabumetone 1,000
Normalized name: nabumetone 1,000 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1,000 mg per day at bedtime
Study: 27809345
Drug: Nebilet HCT™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebilet HCT™ (nebivolol 5 mg + hydrochlorothiazide 12.5 mg tablet)
Study: 27809345
Drug: Nebilet™ (nebivolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebilet™ (nebivolol 5 mg tablet)
Study: 27809345
Drug: Clorana™ (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorana™ (hydrochlorothiazide 25 mg tablet)
Study: 26229445
Drug: Paracetamol (APAP)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (APAP)
Study: 23258770
Drug: Non-anti-angiogenic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anti-angiogenic therapy (TACE)
Study: 17497441
Drug: 80 microg
Normalized name: Folic acid 80 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 microg intradermal (ID) vaccination
Study: 17497441
Drug: 160 microg
Normalized name: Glycopyrronium (as glycopyrrolate) 160 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 microg intramuscular (IM) vaccination
Study: 7709991
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 micrograms twice a day
Study: 3593906
Drug: Ciramadol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol (30 mg) administered in a fasting state
Study: 3593906
Drug: Ciramadol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol (30 mg) administered in a postprandial state
Study: 29334874
Drug: Telemedicine‐Enhanced Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine‐Enhanced Antidepressant Management intervention delivered in VA community‐based outpatient clinics (CBOCs)
Study: 1355595
Drug: Metoprolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol therapy
Study: 23921199
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow oxygen therapy (NHF) at 45 litre min(‐1)
Study: 23921199
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow oxygen therapy (NHF)
Study: 21914365
Drug: salmeterol/fluticasone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol/fluticasone (50 µg/500 µg)
Study: 21914365
Drug: salbutamol/ipratropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol/ipratropium bromide (120 µg/21 µg)
Study: 18344725
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (starting dose 5 mg/d, mean end-point dose of 11.0 mg/d)
Study: 11739305
Drug: Muscarinic receptor
Normalized name: Muscarinic receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscarinic receptor density measurement using PET with (11)C‐MQNB
Study: 11739305
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate (HR) response to intravenous infusion of isoproterenol (5 minutes after 2 mg of atropine, 5, 10, and 15 ng/kg per minute during 5 minutes per step)
Study: 8390240
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (25 mg) of naltrexone
Study: 8390240
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (100 mg) of naltrexone
Study: 8390240
Drug: Naltrexone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (both doses)
Study: 3080221
Drug: FUDR 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUDR 0.3 mg/kg/day for 2 weeks, mitomycin C 15 mg/m2 over 1 hour every 8 weeks, BCNU 150 mg/m2 over 1 hour every 8 weeks via hepatic artery
Study: 3080221
Drug: Single-agent FUDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent FUDR (planned for future randomized trial)
Study: 29104132
Drug: Adalimumab in
Normalized name: adalimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab in combination with azathioprine
Study: 24710856
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) maintenance treatment
Study: 20456838
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) treatment (Jiangya Capsule)
Study: 20456838
Drug: Integrative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative treatment (Jiangya Capsule plus nimodipine)
Study: 20456838
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) group (nimodipine plus Jiangya Capsule simulation)
Study: 17157857
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DINAC
Study: 17157857
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg DINAC
Study: 17157857
Drug: DINAC (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: DINAC (both doses)
Study: 14982314
Drug: Increased cardiovascular
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased cardiovascular fitness (on-treatment analysis)
Study: 11789243
Drug: Lixin Pill
Normalized name: Prolixin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixin Pill (LXP)
Study: 11789243
Drug: LXP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LXP plus small dosage of digoxin
Study: 11789243
Drug: Ordinary dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary dosage of digoxin
Study: 1734794
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (5 mg/kg)
Study: 27050028
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (O3FAs), n = 65, twice daily for 6 months
Study: 27050028
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil), n = 65, twice daily for 6 months
Study: 24841975
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of one of seven commonly used AML salvage regimens (including high-dose cytarabine, multiagent chemotherapy, hypomethylating agents, hydroxyurea, and supportive care)
Study: 22749258
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of fingolimod (0.5 mg/d) for 2 years
Study: 20547017
Drug: HT-group (Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT-group (Estradiol 2 mg + NETA 1 mg)
Study: 20547017
Drug: HT+C-group (Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT+C-group (Estradiol 2 mg + NETA 1 mg + 800 mg clodronate)
Study: 17878466
Drug: ICS and
Normalized name: HYPNOTICS AND SEDATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS and long-acting beta-agonist combination therapy
Study: 12197998
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg ascorbate/d)
Study: 7772440
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 1 ml injected into the lumen of the vas deferens
Study: 7772440
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 1 ml injected into the lumen of the vas deferens
Study: 6270295
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of cannabidiol (CBD)
Study: 31301919
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine 1
Study: 31301919
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine 2
Study: 22006379
Drug: High-dose ambroxol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ambroxol (990 mg/day) for 5 consecutive days after operation
Study: 22006379
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ambroxol treatment)
Study: 19713235
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g psyllium
Study: 19713235
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g bran
Study: 19713235
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g placebo (rice flour)
Study: 17311305
Drug: BCG (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (81 mg)
Study: 17311305
Drug: BCG (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (27 mg)
Study: 17311305
Drug: BCG (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (27 mg) + IFN-alpha
Study: 17311305
Drug: BCG (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (81 mg) or BCG (27 mg) + IFN-alpha
Study: 12086724
Drug: Formulation H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation H
Study: 12086724
Drug: Formulations F,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations F, G, H and I
Study: 2698903
Drug: 5682 SE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5682 SE (2 tablets per day for 2 months)
Study: 2698903
Drug: Diosmin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin (900 mg per day for 2 months)
Study: 1190094
Drug: Information condition
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information condition subjects administered the SHSS A in standardized manner
Study: 1190094
Drug: No information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: No information subjects administered the SHSS A with usual rapport section omitted
Study: 11706694
Drug: Poly-L-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-L-lactic acid screws
Study: 7921429
Drug: Salmeterol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol treatment
Study: 23446962
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HPD), 1.2 g·kg BW(-1)·d(-1)
Study: 23446962
Drug: Normal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein diet (NPD), 0.8 g·kg BW(-1)·d(-1)
Study: 15257930
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation (ASCT) after induction therapy with idarubicin, cytarabine, and etoposide.
Study: 15257930
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with idarubicin, cytarabine, and etoposide.
Study: 29671767
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein Hydrolysate (3.3, 5.0, or 7.5 g of protein)
Study: 29671767
Drug: Free Amino
Normalized name: FREE AMINO ACID DIET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free Amino Acid Mixture (2.5 g)
Study: 27644034
Drug: EBA-175 RII-NG
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBA-175 RII-NG vaccine (5 μg, 20 μg, or 80 μg) administered intramuscularly at 0, 1, and 6 months
Study: 27644034
Drug: EBA-175 RII-NG
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBA-175 RII-NG vaccine
Study: 19458364
Drug: Dipyridamole plus
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole plus aspirin (200 mg dipyridamole and 25 mg aspirin, twice daily)
Study: 15532134
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch (20 micrograms of ethinylestradiol and 150 micrograms of norelgestromin)
Study: 9597955
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (CT) and radiotherapy (RT)
Study: 7941816
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the evening (10.00 p.m.)
Study: 7941816
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the morning (6.00 a.m.)
Study: 7941816
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the evening (10.00 p.m.)
Study: 7941816
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the morning (6.00 a.m.)
Study: 28825515
Drug: Egg-based, trivalent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-based, trivalent, inactivated split influenza vaccine
Study: 25764482
Drug: Topical natamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical natamycin, 5%
Study: 25764482
Drug: Topical voriconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical voriconazole, 1%
Study: 25764482
Drug: Topical natamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical natamycin, 5% (subgroup analysis for Fusarium species)
Study: 25764482
Drug: Topical voriconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical voriconazole, 1% (subgroup analysis for Fusarium species)
Study: 25764482
Drug: Topical natamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical natamycin, 5% (for Aspergillus or other non-Fusarium species)
Study: 25764482
Drug: Topical voriconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical voriconazole, 1% (for Aspergillus or other non-Fusarium species)
Study: 22990223
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of nicotine replacement therapy (NRT)
Study: 22990223
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of nicotine replacement therapy (NRT)
Study: 20529203
Drug: Self-management workshop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management workshop (6-week intervention, weekly 2-hour sessions based on cognitive-behavioral principles)
Study: 15223002
Drug: L-DOPA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (400 mg) + CarbiDOPA (100 mg)
Study: 2434802
Drug: Perindopril (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4, 8, and 16 mg)
Study: 30963205
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg/kg IV
Study: 24329696
Drug: Estrogen substitution
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen substitution therapy (follow-up study)
Study: 19339404
Drug: Walnut diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut diet (42.5 g walnuts/10.1 mJ)
Study: 19339404
Drug: Fish diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish diet (113 g salmon, twice/wk)
Study: 11730735
Drug: (99m)Tc‐pertechnetate vaginally
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc‐pertechnetate vaginally (0.2 mL)
Study: 11730735
Drug: (99m)Tc‐pertechnetate vaginally
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc‐pertechnetate vaginally (0.2 mL) with sealed cervical canal
Study: 9200272
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg per day
Study: 8254957
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving treatment, quadrantectomy with or without immediate reconstruction, axillary dissection, internal mammary biopsy, and breast irradiation
Study: 2888736
Drug: Ro 23-0364
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 23-0364 (0.25 mg)
Study: 2888736
Drug: Ro 23-0364
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 23-0364 (0.5 mg)
Study: 2888736
Drug: Ro 23-0364
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 23-0364 (1.0 mg)
Study: 27031850
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with chemotherapy
Study: 1245939
Drug: Inactivated monovalent
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated monovalent influenza B vaccine (0.25 ml containing 250 chick cell agglutinating units)
Study: 30663593
Drug: Vincristine 1·4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1·4 mg/m2 [maximum 2·0 mg]
Study: 23112275
Drug: Silicone intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone intranasal septal splint (INS)
Study: 19736359
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride therapy for 6 months
Study: 17034955
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment for 8 weeks
Study: 12759221
Drug: TPNGLN (glutamine-supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPNGLN (glutamine-supplemented TPN, 0.4 g.kg‐1.day‐1)
Study: 12759221
Drug: TPN (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN (conventional parenteral nutrition)
Study: 8290465
Drug: Povidone-iodine alcoholic
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine alcoholic solution
Study: 8290465
Drug: Povidone-iodine aqueous
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine aqueous solution
Study: 3984975
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium loading dose of 550 mg
Study: 21210268
Drug: Menthol drops
Normalized name: MENTHOL 20 mg ORAL LOZENGE [Menthol Drops Dollar General Severe 45ct]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol drops applied topically with standard therapy (topical clotrimazole)
Study: 21210268
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standard therapy (topical clotrimazole)
Study: 16142002
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel containing gaïazulene and dimeticone